` MDC (Medlab Clinical Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MDC
vs
S
S&P/ASX 300

Over the past 12 months, MDC has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
MDC vs S&P/ASX 300

Loading
MDC
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MDC vs S&P/ASX 300

Performance Gap Between MDC and AXKO
HIDDEN
Show

Performance By Year
MDC vs S&P/ASX 300

Loading
MDC
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Medlab Clinical Ltd vs Peers

S&P/ASX 300
MDC
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Medlab Clinical Ltd
Glance View

Market Cap
15.1m AUD
Industry
Biotechnology

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.

MDC Intrinsic Value
HIDDEN
Show
Back to Top